Top Page
Antares Vision SpA
(AV)
Antares Vision SpA (AV) vs. iShares MSCI Italy ETF (EWI)
Antares Vision SpA Business Overview & Revenue Model
Antares Vision SpA Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 210.96M | 207.49M | 210.02M | 201.31M | 179.13M | 121.11M |
| Gross Profit | 61.98M | 147.11M | 22.55M | 155.08M | 144.78M | 93.32M |
| EBITDA | 5.42M | 13.94M | -68.77M | 17.77M | 33.36M | 22.70M |
| Net Income | -9.78M | -18.77M | -99.65M | 1.63M | 12.40M | 18.16M |
Balance Sheet | ||||||
| Total Assets | 378.34M | 419.78M | 436.44M | 581.99M | 507.61M | 362.92M |
| Cash, Cash Equivalents and Short-Term Investments | 49.07M | 65.29M | 56.61M | 87.92M | 118.48M | 129.19M |
| Total Debt | 140.03M | 151.55M | 163.99M | 151.30M | 145.20M | 158.45M |
| Total Liabilities | 243.63M | 259.74M | 268.72M | 273.14M | 235.21M | 227.76M |
| Stockholders Equity | 134.69M | 159.84M | 167.81M | 308.75M | 272.33M | 134.83M |
Cash Flow | ||||||
| Free Cash Flow | 20.63M | 33.18M | -23.99M | -28.07M | 13.32M | 9.12M |
| Operating Cash Flow | 31.22M | 43.80M | -6.79M | -10.47M | 29.82M | 16.06M |
| Investing Cash Flow | -4.57M | -6.34M | -9.99M | -22.14M | -136.76M | -54.84M |
| Financing Cash Flow | -22.05M | -22.91M | -3.07M | 14.39M | 88.37M | 50.13M |
Antares Vision SpA Technical Analysis
Antares Vision SpA Peers Comparison
Antares Vision SpA Corporate Events
Antares Vision has announced the resignation of its CEO, Gianluca Mazzantini, as part of a consensual resolution agreement. Fabio Forestelli has been appointed as the new CEO, while Stefano De Rosa has been co-opted as an Executive Director. The company is focused on strengthening its market position and generating sustainable growth, with a renewed commitment to innovation and customer value.
The most recent analyst rating on (IT:AV) stock is a Buy with a EUR5.40 price target. To see the full list of analyst forecasts on Antares Vision SpA stock, see the IT:AV Stock Forecast page.
Antares Vision Group has partnered with Guinea-Bissau to implement a national pharmaceutical traceability system, marking a significant advancement in digital healthcare in West Africa. This collaboration includes expanding local pharmaceutical production capacities and extending traceability to the medical device sector, positioning Guinea-Bissau as a leader in digital healthcare within the ECOWAS region. The initiative, which will begin generating revenue in late 2025, aims to enhance patient safety and regulatory compliance through the National Drug Catalog and a robust inspection program to reduce illicit imports. The upcoming launch of the AVGroupHub digital platform will facilitate registration for all stakeholders, aligning with regulations effective in March 2026.
The most recent analyst rating on (IT:AV) stock is a Buy with a EUR5.20 price target. To see the full list of analyst forecasts on Antares Vision SpA stock, see the IT:AV Stock Forecast page.
Antares Vision S.p.A. is set for a significant ownership change as Crane NXT, Co. plans to acquire a 58.7% stake through a new joint-stock company, BidCo, with the aim of delisting Antares Vision from Euronext Milan. This acquisition involves a series of agreements, including a sale and purchase agreement and an investment agreement, which outline the transfer of shares, management commitments, and future corporate governance. The move is expected to impact Antares Vision’s market positioning and operations, potentially influencing stakeholders involved in the company’s governance and strategic direction.
The most recent analyst rating on (IT:AV) stock is a Buy with a EUR5.20 price target. To see the full list of analyst forecasts on Antares Vision SpA stock, see the IT:AV Stock Forecast page.
Antares Vision S.p.A., a company listed on the Italian stock exchange, has announced a change in the status of one of its board members. Lawyer Vittoria Giustiniani has lost her independence requirements due to her association with BonelliErede, a law firm involved in a recent acquisition of a controlling stake in Antares Vision by Crane NXT Co. This change does not affect the company’s compliance with regulations regarding the number of independent directors on its board.
The most recent analyst rating on (IT:AV) stock is a Buy with a EUR5.20 price target. To see the full list of analyst forecasts on Antares Vision SpA stock, see the IT:AV Stock Forecast page.
Antares Vision S.p.A. has announced the availability of its Half-Yearly Financial Report for the period ending 30 June 2025. The report, approved by the Board of Directors, is accessible to the public through the company’s registered office, the ‘1INFO’ storage mechanism, and the company’s website. This release underscores the company’s commitment to transparency and provides stakeholders with insights into its financial performance for the first half of the year.
The most recent analyst rating on (IT:AV) stock is a Buy with a EUR5.20 price target. To see the full list of analyst forecasts on Antares Vision SpA stock, see the IT:AV Stock Forecast page.
Antares Vision Group reported a 14% year-over-year increase in orders for the first half of 2025, with significant growth in the Americas and Asia & Oceania, despite geopolitical tensions affecting the second quarter. The company doubled its adjusted EBITDA to €7.3 million and maintained net debt levels, while its L5 Government Solutions business showed promising prospects in Africa and the Middle East, positioning it as a growth driver for future profitability.
The most recent analyst rating on (IT:AV) stock is a Buy with a EUR5.20 price target. To see the full list of analyst forecasts on Antares Vision SpA stock, see the IT:AV Stock Forecast page.
Antares Vision Group has signed a strategic agreement with the Medicines Control Agency (MCA) of Gambia to implement DIAMIND Government Solutions, enhancing pharmaceutical traceability and regulatory oversight in the country. This initiative, starting in late 2025, aims to secure Gambia’s pharmaceutical supply chain and integrate digital systems into MCA’s operations, with support from the Africa Agenda Network. The project is expected to improve drug safety, transparency, and regulatory efficiency, aligning with Gambia’s healthcare transformation goals and expanding Antares Vision Group’s presence in the African market.
The most recent analyst rating on (IT:AV) stock is a Buy with a EUR5.20 price target. To see the full list of analyst forecasts on Antares Vision SpA stock, see the IT:AV Stock Forecast page.
Antares Vision Group has entered into a partnership with a US multinational in the Fast-Moving Consumer Goods sector to implement a global serialization and traceability platform for the cosmetics supply chain. This collaboration highlights Antares Vision’s expertise in regulatory compliance and supply chain visibility, marking a significant advancement in their growth and innovation strategy, particularly in the cosmetic market.
The most recent analyst rating on (IT:AV) stock is a Buy with a EUR4.00 price target. To see the full list of analyst forecasts on Antares Vision SpA stock, see the IT:AV Stock Forecast page.